Medical Cannabis for Epilepsy — Switzerland 2026
CBD is the best-evidenced cannabis indication in certain epilepsy forms — with a Swiss-reimbursed medicine: Epidyolex®.
Epidyolex® (pure CBD 100 mg/ml) is approved and reimbursed in Switzerland for Dravet syndrome, Lennox-Gastaut syndrome and tuberous sclerosis (children from 2 years and adults). Reduces seizure frequency by 30–50 %. Other resistant epilepsies possible off-label. Prescription: neurologist/epileptologist. CannabisClub members: 50 CHF instead of 190.
Evidence — strongest in cannabis medicine
Three registration trials (Devinsky 2017, Thiele 2018, Devinsky 2018), >500 children: Epidyolex reduces seizure frequency by 39–45 % vs 13–17 % on placebo.
Tuberous sclerosis (Thiele 2021): 48 % reduction. FDA, EMA and Swissmedic approved.
Preparations & dosing
Epidyolex®: start 2.5 mg/kg twice daily, titrate to 5–10 mg/kg twice daily. Reimbursed for approved indications.
Magistral CBD oils: off-label alternative, 5–20 mg/kg/day, Art. 71a HIO coverage possible.
Save as a CannabisClub member
Even with reimbursed Epidyolex, consultation and follow-up are on you. External consult: 180–220 CHF. Member: 50 CHF flat — on quarterly follow-up that's 560 CHF saved per year.
Registration is free. Become a member now.
FAQ
Is Epidyolex the same as shop CBD?
No. Epidyolex is pharma-grade 100 mg/ml THC-free CBD, Swissmedic approved. Shop CBD is a food supplement without guaranteed dose and not approved for epilepsy.
Does insurance cover Epidyolex?
Yes, for approved indications (Dravet, Lennox-Gastaut, tuberous sclerosis) via the specialty list. Cost without insurance: 12,000–30,000 CHF/year.
What does CannabisClub membership save?
Consultation and digital renewal at 50 CHF instead of 190 CHF. Quarterly follow-up: 560 CHF/year. Registration is free.
Cannabis for Epilepsy — Epidyolex & Prescription Switzerland 2026 (Members 50 CHF)